Revenue (USD, millions)

Cost of sales (USD, millions)

Selling, general and administrative expenses (USD, millions)

Research and development expenses (USD, millions)

Amortization of intangible assets (USD, millions)

Restructuring charges and certain acquisition and divestiture-related costs (USD, millions)

Interest expense, net of capitalized interest (USD, millions)

Other (income)/deductions–net (USD, millions)

Income before provision for taxes on income (USD, millions)

Provision for taxes on income (USD, millions)

Net income before allocation to noncontrolling interests (USD, millions)

Less: Net income/(loss) attributable to noncontrolling interests (USD, millions)

Net income attributable to Zoetis Inc. (USD, millions)

Basic Earnings per share attributable to Zoetis Inc. stockholders (USD)

Diluted Earnings per share attributable to Zoetis Inc. stockholders (USD)

96836b4c7344a7814849781991fb6b3257ad60c24e1f1125d486d08e7576ffa1

Cash and cash equivalents (USD, millions)

Accounts receivable, less allowance for doubtful accounts (USD, millions)

Inventories (USD, millions)

Other current assets (USD, millions)

Total current assets (USD, millions)

Property, plant and equipment, less accumulated depreciation (USD, millions)

Operating lease right‐of‐use assets (USD, millions)

Goodwill (USD, millions)

Identifiable intangible assets, less accumulated amortization (USD, millions)

Noncurrent deferred tax assets (USD, millions)

Other noncurrent assets (USD, millions)

Total assets (USD, millions)

Current portion of long‐term debt (USD, millions)

Accounts payable (USD, millions)

Dividends payable (USD, millions)

Accrued expenses (USD, millions)

Accrued compensation and related items (USD, millions)

Income taxes payable (USD, millions)

Other current liabilities (USD, millions)

Total current liabilities (USD, millions)

Long‐term debt, net of discount and issuance costs (USD, millions)

Noncurrent deferred tax liabilities (USD, millions)

Operating lease liabilities (USD, millions)

Other taxes payable (USD, millions)

Other noncurrent liabilities (USD, millions)

Total liabilities (USD, millions)

Common stock (USD, millions)

Treasury stock, at cost (USD, millions)

Additional paid‐in capital (USD, millions)

Retained earnings (USD, millions)

Accumulated other comprehensive loss (USD, millions)

Total Zoetis Inc. equity (USD, millions)

Equity attributable to noncontrolling interests (USD, millions)

Total equity (USD, millions)

Total liabilities and equity (USD, millions)

2da5e09c03d1442b41178d399ee850ac0d757d488bc75635e22f3e981a301190

Depreciation and amortization expense (USD, millions)

Share‐based compensation expense (USD, millions)

Asset write‑offs and asset impairments (USD, millions)

Provision for losses on inventory (USD, millions)

Other non‑cash adjustments (USD, millions)

Net cash provided by operating activities (USD, millions)

Capital expenditures (USD, millions)

Purchase of investments (USD, millions)

Proceeds from derivative instrument activity, net (USD, millions)

Net proceeds from sale of assets (USD, millions)

Other investing activities (USD, millions)

Net cash used in investing activities (USD, millions)

Change in short‑term borrowings, net (USD, millions)

Purchases of treasury stock, including excise taxes paid (USD, millions)

Cash dividends paid (USD, millions)

Net cash used in financing activities (USD, millions)

Effect of exchange‑rate changes on cash and cash equivalents (USD, millions)

Net (decrease)/increase in cash and cash equivalents (USD, millions)

Income taxes paid (Supplemental) (USD, millions)

Interest, net of capitalized interest (Supplemental) (USD, millions)

Deferred taxes (USD, millions)

Accounts receivable (USD, millions)

Other assets (USD, millions)

Other liabilities (USD, millions)

Other tax accounts, net (USD, millions)

Cash and cash equivalents at beginning of period (USD, millions)

Cash and cash equivalents at end of period (USD, millions)

02e39cd4bb40a8d9d8bfcbd76121af9e5dc119dc853534abdedb37150bbddbb6

9c9420f628abc83bd3aa31177112533b418c48a6d1628db46baf507e83309a3a

Adjustments for Non-Cash Items [USD, M]

Stock-Based Compensation [USD, M]

Changes in Working Capital [USD, M]

Capital Expenditures (CapEx) [USD, M]

Proceeds from / Repayments of Debt [USD, M]

Share Repurchases [USD, M]

Dividend Payments [USD, M]

Net Change in Cash [USD, M]

4583cf37430d14d0319e3348d2cf4efd9b27befb064bbb4bf93b3ce8d7c1883c

328beb3b5450153ea55b905fd859a29eb2fe23d44b9b693aabeabf9d344a07a1

Price growth (percent)

Volume growth from new products (percent)

Volume growth from other in-line products (percent)

Volume growth from key dermatology products (percent)

1e7aa41ec68053597f5d2a2a598ae4f0f66154af7393915652ad7168b3771b8c

9f45eb419f3f647711b3617754b5605e76d5f542a4fb070a5fce7952822ce1f3

13ae08c719c135b27c88e20b465e02e32567c77a4dc0f9b224ff9db689817b9e

Zoetis (ZTS)

Financials